Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
about
Epigenetic treatment of solid tumours: a review of clinical trialsEpigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor HypoxiaRole of MTA2 in human cancerDecitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivoFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentClinical Toxicities of Histone Deacetylase Inhibitors.Vorinostat in solid and hematologic malignanciesPhase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA).The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study.Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.Interpreting clinical assays for histone deacetylase inhibitors.Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities.Epigenetic regulation of microRNAs controlling CLDN14 expression as a mechanism for renal calcium handlingA pharmacogenomic method for individualized prediction of drug sensitivityTargeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.Targeted inhibition of histone deacetylases and hedgehog signaling suppress tumor growth and homologous recombination in aerodigestive cancers.Clinical efficacy of vorinostat in a patient with leiomyosarcoma.Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.Negative effect of cyclin D1 overexpression on recurrence-free survival in stage II-IIIA lung adenocarcinoma and its expression modulation by vorinostat in vitro.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.Derailed estrogen signaling and breast cancer: an authentic couple.Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agentsEpigenetic therapy: use of agents targeting deacetylation and methylation in cancer management.Epigenetic therapy in lung cancer.Epigenetics and colorectal cancer pathogenesisComparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancerExpression of estrogenicity genes in a lineage cell culture model of human breast cancer progression.Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid MalignanciesTargeting histone deacetylases for the treatment of diseaseThe inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidationPreclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.Epigenetics in cancer stem cells.Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
P2860
Q26773803-57898A24-1ABE-4A7F-892C-EB2492481E68Q26783014-FED7334D-7DA4-4BE2-BE3F-53528A7CB2B5Q28251565-27DB0379-83C2-4ED9-B1C6-335B12C1B130Q28263221-7664F936-BFDA-4316-B77F-DC8B8B3A81C9Q28533949-3BA94706-A308-4BA8-A74C-BA1E6AF56F79Q31135325-D2D71758-20A9-4F13-A76A-AF7470335593Q33385544-31B6629A-44D3-41F4-B477-99A30CE2A41DQ33408000-E0D4B35E-5A78-460D-9C6C-849ED1387A19Q33590788-AC3C93A6-ECEC-40D3-8CE5-0F2F01EE9E03Q33829390-3FEF2C41-7E29-467D-A6E1-9A2F75650C58Q34171631-D9796761-0625-4698-BDF3-D7809FA67986Q34371189-A16E0959-BDC1-421C-A250-A848652EF242Q34416979-B9791123-4D38-4B86-9E9D-F24AAA07D0B6Q34416994-4E32FFD3-3F89-43E5-B144-BC792C0C8AB0Q35000789-4AA4DE1E-0D96-4F8F-8822-AC8F772CFF9CQ35003657-241AC07B-4CDD-48A4-A75A-6EEDCB6C5EA4Q35042270-4A5278B4-1B39-4273-8CA7-30D896151B2CQ35124237-484DBF5F-7CF6-4004-86A4-D6311B6D7DC2Q35176386-C1E1428C-CDDC-4D44-9CA9-8EC2AF95B489Q35246513-6CB793CB-3745-4343-BA65-0DFC3A510374Q35757980-1DE94D45-6FA6-408A-A0EB-0E4DC5B0E1E8Q35789686-306592AE-8212-4131-B8CD-7B6DF63D642AQ35845089-37D349B4-1570-4D51-8402-155B69BB0CA2Q35872619-34C50113-71CC-44AA-AA43-9230C818D813Q35939690-007C2A32-59F0-4B7B-8471-70B386AC5A55Q35964716-3D3D642E-7E7D-4605-B1D3-E27EFF3A1163Q36589361-E953F098-9762-45B8-B5C4-454F81BA3667Q36645808-05E73E74-5965-4C8D-B0C8-9463D1A6BEE0Q36738463-3862AC1D-CA78-4E6A-9EEB-32883CB8EC38Q36885903-FA3FD567-0F9F-4E56-A49F-9081ECA27EF0Q37061792-CF213108-4BF9-49ED-BA1A-06681E0E9A25Q37093273-1A26F078-F2BD-4374-BBEF-16325C2091BDQ37169705-0678FE5E-5848-4D13-AB24-70D2F9E60BCAQ37226511-F7D01939-AF32-4157-9C93-6E7DFB8B504CQ37296159-447AEF2C-A1FD-44BF-87B5-51B65D86A095Q37315202-9405E83F-801A-48BC-861A-17399546180BQ37421431-95920FB7-1690-42BA-8BC4-3E318EE5A61DQ37503780-93EE81B4-B50E-4E0B-82C0-76CC220144C1Q37618640-C6CECE04-CEF2-4095-A4A2-AAC63C67AA44Q37902054-63938650-46A8-4F32-ADD8-C687DB913E0E
P2860
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Early phase II trial of oral v ...... or non-small cell lung cancer.
@ast
Early phase II trial of oral v ...... or non-small cell lung cancer.
@en
type
label
Early phase II trial of oral v ...... or non-small cell lung cancer.
@ast
Early phase II trial of oral v ...... or non-small cell lung cancer.
@en
prefLabel
Early phase II trial of oral v ...... or non-small cell lung cancer.
@ast
Early phase II trial of oral v ...... or non-small cell lung cancer.
@en
P2093
P1476
Early phase II trial of oral v ...... or non-small cell lung cancer.
@en
P2093
Herlinde Dumez
Johan Vansteenkiste
Justin L Ricker
Sophia S Randolph
P2888
P304
P356
10.1007/S10637-008-9131-6
P577
2008-04-19T00:00:00Z
P6179
1038891516